HPS Pharmacies wish to advise that Boehringer Ingelheim intends to discontinue Metalyse® 40mg as follows:

Metalyse® Powder for Injection
Tenecteplase (rch) 40mg
ARTG 75012

The 40mg presentation of Metalyse® will be deleted in September 2024, with stock predicted to be depleted by the end of January 2025. The decision to discontinue Metalyse® 40mg is due to low and diminishing demand for this presentation in Australia. This will also allow production to be streamlined for the 50mg presentation.

Metalyse® is also continuing to experience a supply shortage that is expected to persist until 31 December 2024. Boehringer Ingelheim is managing the supply of Metalyse® and anticipates that supplies of Metalyse® 50mg will be adequate to meet the agreed allocations for 2024. The conservation strategies recommended by the Therapeutic Goods Administration (TGA) continue to apply.

In addition, an internationally-registered brand of tenecteplase 50mg is approved for supply in Australia under section 19A of the Therapeutic Goods Act 1989. This product is also subsidised under the existing PBS listing for tenecteplase.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Boehringer Ingelheim on (02) 8875 8800 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates